FDA Released Proposed Biosimilar Fee Program
The agency has unveiled its draft commitment letter for the upcoming Biosimilar User Fee Act IV program.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you support the proposed regulatory changes to speed up the FDA biosimilar review process?
The FDA published a proposed commitment letter for the BsUFA IV program, aimed at streamlining biosimilar application reviews. The agreement seeks to enhance regulatory efficiency before the current authorization expires in September 2027.
Why it matters
These proposed changes are designed to simplify the regulatory process for biosimilar manufacturers by consolidating fee structures and supplement categories. Streamlining these reviews is intended to improve market access for more affordable biologic alternatives.
The proposal introduces specific Category 1 and Category 2 supplement review timelines of four and six months, respectively. These targets apply to 90% of submissions under the new structure.
The players
Food and Drug Administration
The United States federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
The details
The proposal consolidates six biosimilar supplement categories into two and eliminates several development fees including initial, annual, and reactivation costs. Furthermore, the agency intends to replace Biosimilar Initial Advisory meetings with Type 2b meetings and will terminate the current Regulatory Science Pilot Program.
Timeline
25 September 2026: The FDA issued the commitment letter notice.
26 October 2026: The agency will hold a public meeting on the program.
September 2027: The current BsUFA III authorization expires.
Roadmap
The transition to BsUFA IV reflects the ongoing evolution of the biosimilar market as it moves toward a more streamlined and standardized regulatory environment. This shift mirrors broader efforts to reduce administrative burdens on developers and accelerate the entry of biosimilar products into the U.S. market.
This proposal could indirectly impact healthcare consumers by potentially lowering the administrative costs for biosimilar manufacturers, which may lead to more competitive pricing for biological medications. However, the impact on individual patients remains dependent on how quickly these firms navigate the new review timelines.
The takeaway
The FDA's proposed changes represent a significant structural shift in how biosimilars are reviewed and regulated in the United States. Stakeholders should prepare for a transition to these new performance goals as the existing authorization period concludes next year.
What happens next
The FDA will hold a public meeting to discuss the proposed BsUFA IV changes on 26 October 2026.
Further reading
For more on the current regulatory environment for biological product development, visit the Biotech section.
Source note: This article includes information reported by Raps.
Live Poll
Do you support the proposed regulatory changes to speed up the FDA biosimilar review process?
